A Phase 2/3 interventional study of BCX7353 in Hereditary Angioedema, HAE and Prophylaxis, sponsored by BioCryst Pharmaceuticals. Completed at 87 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by BioCryst Pharmaceuticals · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing berotralstat in Angioedemas, Hereditary — 1 open to participants now, 2 under way, 2 of them phase 3. berotralstat · Angioedemas, Hereditary.
Among the 11 studies testing berotralstat in Angioedemas, Hereditary, this one has the largest enrollment, is one of 3 that started in 2018, is the only one in phase 2/3, and was the 7th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies testing berotralstat in Angioedemas, Hereditary is open now, in 11 countries. Recruiting first, the newest first:
BioCryst Pharmaceuticals · Sites in Canada, Czechia, France and 8 more countries
Ages 2+
By country, each count listing its studies:
berotralstat: first FDA approval 2020 (ORLADEYO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 5
First in 2015; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 387 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 58 across the 11 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
BioCryst Pharmaceuticals is the lead sponsor of 54 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals: 2 open now, 5 under way, 4 of them phase 3. Of 16 finished, 7 (44%) have results posted.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2/3, and was the 12th registered.
BioCryst Pharmaceuticals’s Angioedemas, Hereditary studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing berotralstat in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioCryst Pharmaceuticals’s 22 in Angioedemas, Hereditary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BCX7353
BCX7353 mg oral capsules administered once daily
Safety & Tolerability
The number and percentage of subjects with treatment-emergent adverse events.
Time frame: Up to 96 weeks (US) / 216 weeks (Rest of World (ROW)).
Incidence of Acute Attacks of Angioedema in Subjects During Treatment
Number of 'adjusted' attacks were assessed. Adjusted attacks included at least 1 symptom of swelling, had a response of 'no' to the diary question, 'In retrospect, could there be an alternative explanation for your symptoms other than an HAE attack (i.e., allergic reaction, viral cold etc.)?', and were considered unique (attack began \> 24 hours from the end of the prior attack). Any attack that began within 24 hours from the end of a prior attack was combined with the prior attack.
Time frame: Up to 96 weeks (US) / 216 weeks (ROW)
The Durability of Response to Treatment
To evaluate if the rate of attacks remains consistent (durable) over time, the monthly attack rate was assessed at 0 to 24 weeks, 24 to 48 weeks, 48 to 96 weeks and 96 weeks until the end of the study. Monthly attack rate was defined as the total number of adjusted HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month.
Time frame: Up to 96 weeks (US) / 216 weeks (ROW)
Patient Reported Quality of Life (QoL) During Treatment
Quality of Life (QoL) specific to hereditary angioedema (HAE) was assessed at baseline and at each study visit until the end of the study. The questionnaire (i.e. AE-QoL) consisted of 17 questions spanning 4 domains (functioning, fatigue/mood, fear/shame, and nutrition). Each AE-QoL question had 5 answer options (scored 1-5), with lower and higher scores indicting less and more adverse impact, respectively. Per-subject scores for each domain were computed using the appropriate scoring algorithm applied to the question response scores for each domain. Per-subject total scores (including all 4 domains) were similarly computed using the question response scores for all 17 questions. The outputs from the scoring algorithm were normalized on a scale ranging from 0 (less adverse impact) to 100 (most adverse impact). The Mean change from baseline (CFB) in AE-QoL total score over time is presented below.
Time frame: Up to 96 weeks (US) / 216 weeks (ROW)
Patient's Satisfaction With Medication During Long Term Administration of Berotralstat
The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scale scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. Note: Subjects in Hong Kong did not complete the TSQM.
Time frame: Up to 96 weeks (US) / 216 weeks (ROW)
| Milestone | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| Started | 100 | 287 |
| Completed | 0 | 1 |
| Not completed | 100 | 286 |
| Withdrew: Physician decision | 0 | 3 |
| Withdrew: Withdrawal by subject | 10 | 23 |
| Withdrew: Perceived lack of efficacy | 29 | 30 |
| Withdrew: Lab abnormality or adverse event (ae) | 7 | 25 |
| Withdrew: Intercurrent illness/medical condition | 2 | 3 |
| Withdrew: Other - not otherwise specified (nos) | 4 | 19 |
| Withdrew: Subject non-compliance | 2 | 5 |
| Withdrew: Discontinuation due to rash | 0 | 1 |
| Withdrew: Subsequent ineligibility | 0 | 2 |
| Withdrew: Berotralstat provided by alternative means (i.e., early access program or commercially available) | 46 | 175 |
The number and percentage of subjects with treatment-emergent adverse events.
| Participants | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| TEAE | 94 | 240 |
| Drug-related TEAE | 58 | 119 |
| TESAE | 23 | 20 |
| Drug-related TESAE | 3 | 1 |
| DMID Grade 3 or 4 TEAE | 18 | 35 |
| Drug-related DMID Grade 3 or 4 TEAE | 7 | 11 |
| TEAE leading to study drug discontinuation | 8 | 28 |
| TEAE leading to study drug interruption | 8 | 32 |
| Drug-related rash | 5 | 5 |
| Drug-related rash leading to study drug discontinuation | 1 | 2 |
Number of 'adjusted' attacks were assessed. Adjusted attacks included at least 1 symptom of swelling, had a response of 'no' to the diary question, 'In retrospect, could there be an alternative explanation for your symptoms other than an HAE attack (i.e., allergic reaction, viral cold etc.)?', and were considered unique (attack began \> 24 hours from the end of the prior attack). Any attack that began within 24 hours from the end of a prior attack was combined with the prior attack.
| Participants | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| Subjects reporting at least 1 attack | 95 | 231 |
| Subjects reporting at least 1 treated attack | 87 | 214 |
| Subjects reporting at least 1 untreated attack | 59 | 99 |
To evaluate if the rate of attacks remains consistent (durable) over time, the monthly attack rate was assessed at 0 to 24 weeks, 24 to 48 weeks, 48 to 96 weeks and 96 weeks until the end of the study. Monthly attack rate was defined as the total number of adjusted HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month.
| HAE attacks per 28 days | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| 0 - 24 weeks | 1.276 ± 1.2254 | 1.079 ± 1.4411 |
| 24 - 48 weeks | 1.005 ± 1.0027 | 0.694 ± 1.0072 |
| 48 - 96 weeks | 1.121 ± 1.9573 | 0.591 ± 0.8217 |
| 96 weeks - End of Study | 0.770 ± 1.0394 | 0.725 ± 0.8395 |
Quality of Life (QoL) specific to hereditary angioedema (HAE) was assessed at baseline and at each study visit until the end of the study. The questionnaire (i.e. AE-QoL) consisted of 17 questions spanning 4 domains (functioning, fatigue/mood, fear/shame, and nutrition). Each AE-QoL question had 5 answer options (scored 1-5), with lower and higher scores indicting less and more adverse impact, respectively. Per-subject scores for each domain were computed using the appropriate scoring algorithm applied to the question response scores for each domain. Per-subject total scores (including all 4 domains) were similarly computed using the question response scores for all 17 questions. The outputs from the scoring algorithm were normalized on a scale ranging from 0 (less adverse impact) to 100 (most adverse impact). The Mean change from baseline (CFB) in AE-QoL total score over time is presented below.
| AE-QoL score - change from baseline | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| Week 4 | -8.85 ± 18.986 | -10.38 ± 17.845 |
| Week 8 | -11.20 ± 19.386 | -10.39 ± 19.690 |
| Week 12 | -11.92 ± 18.484 | -11.47 ± 18.561 |
| Week 24 | -11.58 ± 17.630 | -11.98 ± 18.724 |
| Week 36 | -11.79 ± 17.377 | -13.53 ± 18.556 |
| Week 48 | -13.60 ± 17.339 | -14.08 ± 19.351 |
| Week 60 | -12.81 ± 15.888 | -16.42 ± 18.568 |
| Week 72 | -13.14 ± 16.774 | -14.93 ± 18.991 |
| Week 84 | -15.25 ± 16.776 | -14.70 ± 17.710 |
| Week 96 | -14.72 ± 15.342 | -17.44 ± 19.701 |
| Week 108 | -14.85 ± 15.077 | -17.06 ± 18.963 |
| Week 120 | -14.21 ± 16.140 | -18.20 ± 18.705 |
| Week 132 | -14.58 ± 15.765 | -16.57 ± 16.151 |
| Week 144 | -13.05 ± 19.678 | -18.40 ± 18.081 |
| Week 156 | -15.53 ± 15.823 | -21.29 ± 20.015 |
| Week 168 | -16.70 ± 13.690 | -22.06 ± 18.281 |
| Week 180 | -21.69 ± 23.014 | -21.94 ± 17.652 |
| Week 192 | -10.29 ± 0 | -18.53 ± 8.860 |
| Week 204 | — | -13.24 ± 11.672 |
| Week 216 | — | -17.65 ± 14.558 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scale scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. Note: Subjects in Hong Kong did not complete the TSQM.
| TSQM score - change from baseline | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| Week 4 | -4.1 ± 35.51 | -1.3 ± 30.48 |
| Week 8 | -0.6 ± 36.29 | -3.6 ± 30.38 |
| Week 12 | 1.5 ± 34.35 | -0.1 ± 31.37 |
| Week 24 | 5.4 ± 34.46 | 1.7 ± 31.77 |
| Week 36 | 5.8 ± 32.00 | -4.4 ± 27.41 |
| Week 48 | 5.5 ± 31.79 | 4.1 ± 27.78 |
| Week 60 | 8.0 ± 30.13 | 3.1 ± 25.89 |
| Week 72 | 9.3 ± 33.33 | 4.5 ± 27.32 |
| Week 84 | 4.2 ± 32.32 | 1.3 ± 20.76 |
| Week 96 | 6.2 ± 35.64 | 5.5 ± 23.44 |
| Week 108 | -7.1 ± 44.61 | -21.4 ± 10.10 |
| Week 120 | 16.3 ± 33.06 | 6.8 ± 22.68 |
| Week 132 | 5.4 ± 41.80 | -5.7 ± 40.85 |
| Week 144 | 18.2 ± 30.85 | 2.2 ± 26.82 |
| Week 156 | 43.7 ± 32.23 | -30.2 ± 32.10 |
| Week 168 | -1.4 ± 22.46 | 6.1 ± 30.24 |
| Week 180 | -7.1 ± 0 | 11.9 ± 21.98 |
| Week 192 | 0 ± 0 | 14.3 ± 8.75 |
| Week 204 | — | 14.3 ± 0 |
| Week 216 | — | 10.7 ± 15.15 |
Collected over Adverse Events (AEs) were reported from time of Informed Consent Form signature until the last follow-up visit, approximately 3 weeks following the last dose of study drug; a period of up to 223 weeks in total. Grade 3 and 4 AEs or AEs deemed at least possibly related to use of study drug, were to be followed until the AE resolved or the subject was in a clinically stable condition with regards to the AE.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 110 mg Followed by 150 mg Berotralstat | 0/100 (0%) | 23/100 (23%) | 94/100 (94%) |
| 150 mg Berotralstat | 0/287 (0%) | 20/287 (7%) | 240/287 (83.6%) |
| Event | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| Hereditary angioedemaCongenital, familial and genetic disorders | 11/100 | 2/287 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/100 | 0/287 |
| Medical observationInvestigations | 2/100 | 1/287 |
| EnteritisGastrointestinal disorders | 2/100 | 0/287 |
| PneumoniaInfections and infestations | 2/100 | 1/287 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/100 | 0/287 |
| Radius fractureInjury, poisoning and procedural complications | 1/100 | 0/287 |
| Hepatic enzyme increasedInvestigations | 1/100 | 0/287 |
| Myocardial infarctionCardiac disorders | 1/100 | 0/287 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/100 | 0/287 |
| Event | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat |
|---|---|---|
| NasopharyngitisInfections and infestations | 33/100 | 59/287 |
| HeadacheNervous system disorders | 23/100 | 34/287 |
| DiarrhoeaGastrointestinal disorders | 14/100 | 42/287 |
| Abdominal painGastrointestinal disorders | 14/100 | 29/287 |
| Upper respiratory tract infectionInfections and infestations | 14/100 | 36/287 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 10/100 | 12/287 |
| Abdominal pain upperGastrointestinal disorders | 10/100 | 18/287 |
| COVID-19Infections and infestations | 10/100 | 20/287 |
| SinusitisInfections and infestations | 10/100 | 15/287 |
| GastroenteritisInfections and infestations | 10/100 | 12/287 |
| Age, Categorical(Participants) | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat | Total |
|---|---|---|---|
| <=18 years | 5 | 23 | 28 |
| Between 18 and 65 years | 93 | 253 | 346 |
| >=65 years | 2 | 11 | 13 |
| Age, Continuous(years) | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat | Total |
|---|---|---|---|
| Mean | 37.6 ± 14.04 | 40.5 ± 15.26 | 39.8 ± 14.99 |
| Sex: Female, Male(Participants) | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat | Total |
|---|---|---|---|
| Female | 62 | 180 | 242 |
| Male | 38 | 107 | 145 |
| Race (NIH/OMB)(Participants) | 110 mg Followed by 150 mg Berotralstat | 150 mg Berotralstat | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 12 | 11 | 23 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 12 | 12 |
| White | 82 | 256 | 338 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 6 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Apr 2022, 50 months.
Results were first posted in Jun 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berotralstat